Centrum Badań Weterynaryjnych Vetcomplex Spółka z Ograniczoną Odpowiedzialnością (KRS 0000447704, NIP 7282791765) is a Polish company, headquartered in Łódź, Łódzkie voivodeship. CENTRUM BADAŃ WETERYNARYJNYCH VETCOMPLEX operates in: Research and experimental development on biotechnology (PKD 72.11.Z). Industry: Research and development. The company has been listed in the National Court Register since February 26, 2013. CENTRUM BADAŃ WETERYNARYJNYCH VETCOMPLEX's most recently reported net revenue was 1.3 M PLN for 2024.
Negative equity
Negative equity in 2 of 7 available reporting years.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Centrum Badań Weterynaryjnych Vetcomplex
Identity
- Name
- Centrum Badań Weterynaryjnych Vetcomplex Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- February 26, 2013
- Registry status as of
- July 11, 2026
- Latest entry
- July 11, 2026
- Founding act
- AKT NOT. Z DNIA 06.12.2012 R , KANCELARIA NOTARIALNA W BEŁCHATOWIE, NOT. JOLANTA MONIKA RYCHTER, REP. A NR 9025/2012
Articles of association history (2)
- December 6, 2012: AKT NOT. Z DNIA 06.12.2012 R , KANCELARIA NOTARIALNA W BEŁCHATOWIE, NOT. JOLANTA MONIKA RYCHTER, REP. A NR 9025/2012
- July 12, 2019: 12.07.2019 R., REP. A NR 4029/2019, NOTARIUSZ ANNA OSKALDOWICZ, KANCELARIA NOTARIALNA W ŁODZI - ZMIENIONO: §5 UST. 1, §6, §7, §8, §9, §10, §11, §12, §13, §14, §15, §16, §17, §18, §19, §20, §21, §22, §23, §24. - USUNIĘTO: §25, §26, §27, §28, §29, §30, §31, §32, §33, §34, §35.
Activities
Main activity
72.11.ZResearch and experimental development on biotechnology
Other activities
Address and contact
- Address
- CZĘSTOCHOWSKA, 38/52, 93-121, ŁÓDŹ, POLSKA
- Voivodeship
- ŁÓDZKIE
- District
- M. ŁÓDŹ
- BIURO@VETCOMPLEX.PL
- Website
- WWW.VETCOMPLEX.PL
- E-delivery address
- AE:PL-95196-33111-RWSIF-22
Risk and payment profile - Centrum Badań Weterynaryjnych Vetcomplex
Credibility rating
48.4 / 100
Average credibility
Insolvency risk
Low
Elevated threat
Closure risk
21
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
1
1/13 yrs
Board changes
1
1/13 yrs
PKD changes
1
1/13 yrs
Name changes
0
0/13 yrs
Data from 13 years of registry activity.
Credibility history
Payment reliability score from 2018–2024
Current: D (48/100)
Trend: deteriorating (-14.0 pts/year)
Słaba wiarygodność płatnicza – wskaźniki finansowe sugerują podwyższone ryzyko opóźnień lub niewykonania zobowiązań.
Trade credit limit history
Standard limit from 2018–2024
Current: 66.0 K PLN
Safe: 19.8 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Centrum Badań Weterynaryjnych Vetcomplex
Founded
February 26, 2013
13 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
ŁÓDŹ
ŁÓDZKIE
Primary PKD
72.11.Z
Research and experimental development on biotechnology
Share capital
1.6 M PLN
15,712 shares total
Shareholders
1
shareholder
Board
3 people
Filed years
7 years
2018–2024 · profitable: 6/7
Registry entries
41
latest: July 11, 2026
Risk signals
Revenue
1.3 M PLN
2024
Net profit
-150.8 K PLN
2024
Assets
355.9 K PLN
2024
Equity
277.2 K PLN
2024
EBITDA
-14.4 K PLN
2024
Valuation
337.8 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Centrum Badań Weterynaryjnych Vetcomplex.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
